| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/19/2002 | US20020132319 Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 09/19/2002 | US20020132296 Human Ste20-like stress activated serine/threonine kinase |
| 09/19/2002 | US20020132275 Methods for detecting the efficacy of anticancer treatments |
| 09/19/2002 | US20020132237 Detecting ovarian cancer humans; obtain sample, incubate with preferential oligonucleotides, monitor hybridization, compare to control, evaluate for cancer |
| 09/19/2002 | US20020132236 Specific inhibitors of ribosome recycling factors (RRF) |
| 09/19/2002 | US20020132224 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis |
| 09/19/2002 | US20020132223 Methods for modulating activity of the FXR nuclear receptor |
| 09/19/2002 | US20020132219 Composition and method for modulating nutrient partitioning |
| 09/19/2002 | US20020132011 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| 09/19/2002 | US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration |
| 09/19/2002 | US20020131951 Biodegradable poly(beta-amino esters) and uses thereof |
| 09/19/2002 | DE10110953A1 Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten Transdermal therapeutic system for administration of partial dopamine-D2 agonists |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2473156A1 Rxr activating molecules |
| 09/19/2002 | CA2458479A1 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof |
| 09/19/2002 | CA2458451A1 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 09/19/2002 | CA2441854A1 Composition for rectal delivery of an oxazolidinone antibacterial drug |
| 09/19/2002 | CA2441495A1 Proteins associated with cell growth, differentiation, and death |
| 09/19/2002 | CA2441210A1 Novel peptide ligands of leukocyte integrins |
| 09/19/2002 | CA2441177A1 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| 09/19/2002 | CA2441088A1 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 09/19/2002 | CA2440973A1 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | CA2440834A1 Anti-epileptogenic agents |
| 09/19/2002 | CA2440773A1 Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| 09/19/2002 | CA2440757A1 Substituted tetracycline compounds as synergistic antifungal agents |
| 09/19/2002 | CA2440647A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |
| 09/19/2002 | CA2440555A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | CA2440433A1 Cell culture system for synthesis of infectious hepatitis c virus |
| 09/19/2002 | CA2440225A1 Taxane prodrugs |
| 09/19/2002 | CA2440163A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor |
| 09/19/2002 | CA2440158A1 Method to obtain microparticles containing a h+, k+-atp-ase inhibitor |
| 09/19/2002 | CA2439920A1 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 09/19/2002 | CA2439774A1 Compositions and methods for non-insulin glucose uptake |
| 09/19/2002 | CA2439735A1 Igf antagonist peptides |
| 09/19/2002 | CA2439612A1 Modulation of smooth muscle cell proliferation |
| 09/19/2002 | CA2439063A1 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| 09/19/2002 | CA2438868A1 Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2437960A1 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 09/19/2002 | CA2437756A1 Nucleic acid-associated proteins |
| 09/19/2002 | CA2436083A1 Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders |
| 09/19/2002 | CA2434611A1 Combined method for treating hormono-dependent disorders |
| 09/18/2002 | EP1241259A1 Peptide having pronociceptive properties |
| 09/18/2002 | EP1240897A1 Pharmaceutical tablet and process for making thereof |
| 09/18/2002 | EP1240822A1 Diabetes onset model mammal |
| 09/18/2002 | EP1240525A2 Sodium channels as targets for amyloid beta |
| 09/18/2002 | EP1240521A2 Identification of disease markers involving mass-based-separation |
| 09/18/2002 | EP1240358A1 T1 receptor-like ligand ii and uses thereof |
| 09/18/2002 | EP1240352A2 Molecules derived from mechanism based drug design |
| 09/18/2002 | EP1240335A2 Proteases |
| 09/18/2002 | EP1240327A2 Interferon-like molecules and uses thereof |
| 09/18/2002 | EP1240323A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/18/2002 | EP1240313A2 Homologues of human heparanase and splice variants thereof |
| 09/18/2002 | EP1240199A2 Method for screening of appetite control agents |
| 09/18/2002 | EP1240197A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1240196A2 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 09/18/2002 | EP1240181A2 Daptomycin analogs as antibacterial agents |
| 09/18/2002 | EP1240168A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 09/18/2002 | EP1240166A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240165A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240153A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1239923A2 Stabilized veterinary compositions comprising more than one antiviral agent |
| 09/18/2002 | EP1239922A2 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator |
| 09/18/2002 | EP1239885A1 Interventions to mimic the effects of calorie restriction |
| 09/18/2002 | EP1239883A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239882A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239881A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239880A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239879A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239878A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239877A2 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN $g(a) V?$g(b) 3? RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 09/18/2002 | EP1239871A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 09/18/2002 | EP1239870A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1239869A2 Tweak receptor |
| 09/18/2002 | EP1239868A2 Use of an immunosuppressant for increasing an antifungal activity of a lipopetide |
| 09/18/2002 | EP1239867A2 Methods for treating and preventing damage to mucosal tissue |
| 09/18/2002 | EP1239862A2 Pharmaceutical preparation for treating tumor diseases |
| 09/18/2002 | EP1239861A2 Combination of cyamemazine and an atypical neuroleptic |
| 09/18/2002 | EP1239860A1 Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-despressants |
| 09/18/2002 | EP1239856A1 Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| 09/18/2002 | EP1239855A2 Method for the prevention and/or treatment of atherosclerosis |
| 09/18/2002 | EP1239854A1 Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 09/18/2002 | EP1239851A1 Treatment of hyperproliferative disorders |
| 09/18/2002 | EP1239848A2 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239844A1 Process for producing nanometer particles by fluid bed spray-drying |
| 09/18/2002 | EP1239829A1 Devices for the delivery of drugs having antiprogestinic properties |
| 09/18/2002 | EP1239825A1 Catechol oximes and their use in cosmetic and dermatological preparations |
| 09/18/2002 | EP1239791A1 Dental prosthesis with means for the release of active substances |
| 09/18/2002 | EP1093380B1 Component b as angiogenic agent in combination with human growth factors |
| 09/18/2002 | EP1039884B1 A method for the prevention and treatment of stunned myocardium |
| 09/18/2002 | EP0954565A4 Adipogenic differentiation of human mesenchymal stem cells |
| 09/18/2002 | EP0842267B1 Mch2, AN APOPTOTIC CYSTEINE PROTEASE, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME |
| 09/18/2002 | EP0831819B1 Method for inhibiting neoplastic disease in mammals |
| 09/18/2002 | CN1370238A Human poly(ADP-ribose) polymerase 2 materials and methods |
| 09/18/2002 | CN1370231A CASB618 polynucleotides and polypeptides and their use |
| 09/18/2002 | CN1370201A Polymeric compsn. for solubilizing poorly water soluble drugs and process for prepn. thereof |
| 09/18/2002 | CN1370082A Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| 09/18/2002 | CN1370081A Synergistic combination |